Recommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease.

What was studied

This is an expert group guideline on late-onset Pompe disease, or LOPD. Pompe disease is a rare disease caused by changes in the GAA gene. It lacks an enzyme that breaks down glycogen. Glycogen builds up in tissues and harms muscles, including heart and skeletal muscle. Late-onset means symptoms start after the first year of life. Weak hip and trunk muscles and breathing problems are common. Enzyme replacement therapy has existed for over 15 years. It is the standard treatment.

What they found

The abstract gives no study results. It says enzyme replacement changes the course of the disease. Its effect reduces over time. New enzyme therapies offer new treatment opportunities. The guideline updates advice on diagnosis, treatment and follow-up. The abstract does not list the specific steps.

What it means for patients

The guideline aims to be a guide for clinical management of the disease. It was written by a group of experts in Pompe disease. It covers diagnosis, treatment and follow-up of people with LOPD. The abstract does not say what doctors do at each stage.

Why it is not certain yet

This is a guideline, not a trial. The abstract does not name the studies behind each point. It gives no evidence ratings. It gives no numbers on outcomes. It says the effect of enzyme therapy reduces over time.

Source

Recommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease.

We restate facts from the source record in our own words. The original wording belongs to its publisher.